S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Closing prices for crude oil, gold and other commodities
2 Important Retail Stock Battles to Watch
Pipeline break spills 45,000 gallons of diesel in Wyoming
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Sinema took Wall Street money while killing tax on investors
Wall Street builds on gains, heads for 4-week winning streak
In Biden's big bill: Climate, health care, deficit reduction
How Much Longer Will It Be Under $1? (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Closing prices for crude oil, gold and other commodities
2 Important Retail Stock Battles to Watch
Pipeline break spills 45,000 gallons of diesel in Wyoming
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Sinema took Wall Street money while killing tax on investors
Wall Street builds on gains, heads for 4-week winning streak
In Biden's big bill: Climate, health care, deficit reduction
How Much Longer Will It Be Under $1? (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Closing prices for crude oil, gold and other commodities
2 Important Retail Stock Battles to Watch
Pipeline break spills 45,000 gallons of diesel in Wyoming
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Sinema took Wall Street money while killing tax on investors
Wall Street builds on gains, heads for 4-week winning streak
In Biden's big bill: Climate, health care, deficit reduction
How Much Longer Will It Be Under $1? (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Closing prices for crude oil, gold and other commodities
2 Important Retail Stock Battles to Watch
Pipeline break spills 45,000 gallons of diesel in Wyoming
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Sinema took Wall Street money while killing tax on investors
Wall Street builds on gains, heads for 4-week winning streak
In Biden's big bill: Climate, health care, deficit reduction
How Much Longer Will It Be Under $1? (Ad)pixel
NASDAQ:VINC

Vincerx Pharma - VINC Earnings Date, Estimates & Call Transcripts

$1.58
+0.10 (+6.76%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.47
$1.64
50-Day Range
$1.29
$1.97
52-Week Range
$1.26
$18.43
Volume
247,951 shs
Average Volume
90,112 shs
Market Capitalization
$33.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.67

Earnings Summary

Upcoming
Earnings Date
Nov. 11Estimated
Actual EPS
(May. 12)
-$0.79 Beat By $0.08
Consensus EPS
(May. 12)
-$0.87
Last Year's Q2 EPS
(5/16/2021)
-$0.46
Skip Charts & View Estimated and Actual Earnings Data

VINC Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

VINC Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Vincerx Pharma Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20222($0.87)($0.87)($0.87)
Q2 20222($0.92)($0.88)($0.90)
Q3 20222($1.00)($0.78)($0.89)
Q4 20222($0.83)($0.66)($0.75)
FY 20228($3.62)($3.19)($3.41)

VINC Earnings Date and Information

Vincerx Pharma last issued its earnings results on May 12th, 2022. The reported ($0.79) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.87) by $0.08. Vincerx Pharma has generated ($3.37) earnings per share over the last year (($3.37) diluted earnings per share). Earnings for Vincerx Pharma are expected to grow in the coming year, from ($2.67) to ($1.96) per share. Vincerx Pharma has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Friday, November 11th, 2022 based off prior year's report dates.

Vincerx Pharma Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
11/11/2022
(Estimated)
        
5/12/2022Q1 2022($0.87)($0.79)+$0.08($0.79)
3/29/2022Q4 2021($0.93)($0.85)+$0.08($1.39)
11/12/2021Q3 2021($0.79)($1.02)($0.23)($0.65)
8/12/20216/30/2021($0.30)($0.12)+$0.18($0.12)
5/16/2021Q1 2021($0.32)($0.46)($0.14)($0.46)












Vincerx Pharma Earnings - Frequently Asked Questions

When is Vincerx Pharma's earnings date?

Vincerx Pharma has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, November 11th, 2022 based off last year's report dates. Learn more on VINC's earnings history.

Did Vincerx Pharma beat their earnings estimates last quarter?

In the previous quarter, Vincerx Pharma (NASDAQ:VINC) reported ($0.79) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.87) by $0.08. Learn more on analysts' earnings estimate vs. VINC's actual earnings.

How much profit does Vincerx Pharma generate each year?

Vincerx Pharma (NASDAQ:VINC) has a recorded net income of -$39.31 million. VINC has generated -$3.37 earnings per share over the last four quarters.

What is Vincerx Pharma's EPS forecast for next year?

Vincerx Pharma's earnings are expected to grow from ($2.67) per share to ($1.96) per share in the next year.

More Earnings Resources from MarketBeat

Upcoming Earnings:
This page (NASDAQ:VINC) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.